FEDERALhearing transcript

Congressional Hearing on Medical Product Manufacturer Communications

Original title: EXAMINING MEDICAL PRODUCT MANUFACTURER COMMUNICATIONS

January 1, 2018

healthcare medical devices pharmaceuticals FDA regulation medical communication

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing explored potential changes to federal law that would dictate what information pharmaceutical and medical device companies can legally share with doctors and insurance companies, which could impact how medical professionals learn about new treatment options.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

Medical product manufacturers

The proposed legislation would change the legal standards for how they communicate information about their drugs and devices.

Healthcare providers

They are the recipients of the information shared by manufacturers, which may influence their treatment decisions.

Patients

Changes in how medical information is shared can impact the types of treatments they are offered or informed about.

What changed

Last recorded activity January 1, 2018.

What's next

Next step not available in the current record.

Summary

This document is a transcript of a 2017 House Subcommittee on Health hearing regarding how medical product manufacturers communicate information about their drugs and devices to healthcare providers and insurers. The hearing examined draft legislation aimed at clarifying the rules for sharing information about products that are still under review or being used for purposes not yet approved by the FDA.

Key Facts

The hearing was held on July 12, 2017, by the House Subcommittee on Health.
The committee reviewed two discussion drafts of legislation regarding the exchange of information about drugs and devices prior to FDA approval.
The hearing addressed the legal standards for 'scientific exchange' and communications regarding 'intended uses' of medical products.
Six expert witnesses provided testimony, including representatives from legal, medical, academic, and patient advocacy backgrounds.
The hearing included the submission of letters from the Academy of Managed Care Pharmacy and the Alliance of Specialty Medicine.

Why It Matters

Frequently Asked Questions

What was the purpose of this hearing?

The hearing was held to discuss how medical product manufacturers communicate information about their products to healthcare professionals and insurers, specifically regarding products not yet approved or used for unapproved purposes.

Did this hearing result in a new law?

No, this was a hearing to discuss draft legislation and gather expert testimony; it did not result in the passage of a law.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Focus on Pre-Approval Communication

The hearing highlights a legislative effort to relax or clarify restrictions on how manufacturers share information about products before they receive full FDA approval.

House Subcommittee on Health

Connected Entities

personKatherine Wolf Khachatourian“Vice President at Qualchoice Health Plan Services, Inc.; witness”Map →

personColeen Klasmeier“Partner at Sidley Austin, LLP; witness”Map →

personMichael C. Burgess“Chairman of the Subcommittee on Health”Map →

personLinda House“President of the Cancer Support Community; witness”Map →

personGene Green“Ranking Member of the Subcommittee on Health”Map →

personAaron S. Kesselheim“Associate Professor of Medicine at Harvard Medical School; witness”Map →

personGeorge Van Hare“President of the Heart Rhythm Society; witness”Map →

personR. Alta Charo“Professor of Law at University of Wisconsin; witness”Map →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100

Significance60
How much this matters to a regular citizen
Controversy40
Intensity of disagreement among stakeholders
Entertainment10
Compellingness for a non-policy-wonk reader
Buzz15
Current news / social attention level

Publisher tools